Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...

Related Keywords

France ,Sydney ,New South Wales ,Australia ,Germany ,Poland ,Monash ,South Australia ,Polish ,German ,French ,Australian ,Chris Basta ,Frederic Triebel ,Jamie Rossjohn ,Corporate Communications ,Korean Intellectual Property Office ,Merck Kga ,Committee For Medicinal Products Human Use ,Data Monitoring Committee ,Monash University ,Immutep Limited ,Globenewswire Inc ,Nasdaq ,Merck Kgaa ,Overall Survival ,Overall Response Rate ,Combined Positive Score ,Integrated Phase ,Metastatic Breast ,Medicinal Products ,Human Use ,Disease Control Rate ,Soft Tissue ,Professor Jamie Rossjohn ,Korean Intellectual Property ,Australian Federal Government ,French Government ,Related Parties ,Non Executive Director ,Executive Director ,Lymphocyte Activation ,Investor Relations ,Markets ,